CGEM

7.41

1.07% -0.08

Handel nachbörslich: 7.41

Cullinan Therapeutics Inc (CGEM)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$7.49

Offen:

$7.28

24-Stunden-Volumen:

600.30K

Relative Volume:

1.37

Marktkapitalisierung:

$433.58M

Einnahmen:

Nettoeinkommen (Verlust:

$-153.16M

KGV:

-2.0081

EPS:

-3.69

Netto-Cashflow:

$-134.48M

1W Leistung:

-7.61%

1M Leistung:

-8.86%

6M Leistung:

-54.65%

1J Leistung:

-55.58%

1-Tages-Spanne:

$7.11

$7.615

1-Wochen-Bereich:

$7.11

$7.90

52-Wochen-Spanne:

$7.11

$30.19

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Firmenname

Cullinan Therapeutics Inc

Sektor

Healthcare (1162)

Branche

Biotechnology (673)

Telefon

617-410-4650

Adresse

ONE MAIN STREET, CAMBRIDGE

Mitarbeiter

111

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

CGEM's Discussions on Twitter

Vergleichen Sie CGEM mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CGEM Cullinan Therapeutics Inc	7.41	433.58M	0	-153.16M	-134.48M	-3.69
VRTX Vertex Pharmaceuticals Inc	474.62	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	33.86B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	30.51B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	25.69B	3.81B	-644.79M	-669.77M	-6.24

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-24	Eingeleitet	UBS	Buy
2024-05-01	Eingeleitet	Stifel	Buy
2024-04-15	Eingeleitet	William Blair	Outperform
2024-02-15	Eingeleitet	Wedbush	Outperform
2023-06-15	Eingeleitet	TD Cowen	Outperform
2022-11-21	Eingeleitet	BTIG Research	Buy
2021-04-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2021-02-02	Eingeleitet	Evercore ISI	Outperform
2021-02-02	Eingeleitet	Morgan Stanley	Equal-Weight
2021-02-02	Eingeleitet	SVB Leerink	Outperform
2021-02-01	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten

Apr 02, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Analysts - Defense World

Apr 02, 2025

Mar 30, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Swiss National Bank - Defense World

Mar 30, 2025

Mar 26, 2025

Charles Schwab Investment Management Inc. Has $5.25 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Mar 26, 2025

Mar 24, 2025

20,273 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Purchased by Connor Clark & Lunn Investment Management Ltd. - Defense World

Mar 24, 2025

Mar 16, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.1% – Time to Sell? - Defense World

Mar 16, 2025

Mar 12, 2025

EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR

Mar 12, 2025

Mar 09, 2025

Morgan Stanley Reaffirms Overweight Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World

Mar 09, 2025

Mar 08, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Recommendation of “Buy” from Analysts - Defense World

Mar 08, 2025

Mar 07, 2025

Cullinan Therapeutics: Promising Pipeline and Upcoming Catalysts Justify Buy Rating - TipRanks

Mar 07, 2025

Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Mar 07, 2025

Mar 06, 2025

New York State Common Retirement Fund Buys 3,200 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Mar 06, 2025

Cullinan Therapeutics (CGEM) to Release Quarterly Earnings on Thursday - Defense World

Mar 06, 2025

Mar 04, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Given "Buy" Rating at HC Wainwright - MarketBeat

Mar 04, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Announces Earnings Results - MarketBeat

Mar 04, 2025

Mar 03, 2025

Q1 Earnings Estimate for CGEM Issued By William Blair - Defense World

Mar 03, 2025

Cullinan Therapeutics’ (CGEM) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 03, 2025

Mar 01, 2025